PYXS PYXIS ONCOLOGY INC

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, March 10, 2025 at 2:20 PM EST at the Leerink Partners Global Healthcare Conference in Miami, Florida.

A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, .

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-201 is designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors.

To learn more, visit  or follow us on  (formerly known as Twitter) and .

Pyxis Oncology Contact

Pamela Connealy

CFO and COO



EN
03/03/2025

Underlying

PYXSPYXIS ONCOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PYXIS ONCOLOGY INC

 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transi...

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company’s strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology’s Board of Directors since the Company’s IPO and a highly experienced biotechnology executive with a proven track record in adv...

February 3, 2026 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvota...

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma 46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combi...

December 18, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology to Participate in Upcoming Investor Conferences

Pyxis Oncology to Participate in Upcoming Investor Conferences BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025: Guggenheim 2nd Annual Healthcare Innovation Conference, Boston, MA, Monday, November 10, 2:30 p.m. ET. – Fireside chat.Stifel 2025 Healthcare Conference, New York, NY, Tuesday, November 11, 4:00 p.m. ET. – Fireside chat. Live webcasts and r...

November 3, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025...

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results -  Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025 -  Clinical update to focus on preliminary data from Phase 1 monotherapy dose expansion study of MICVO in 2L/3L R/M HNSCC patients, including from both post platinum & PD-1 and post EGFR & PD-1 arms, and preliminary data from Phase 1/2 combination dose escalation study of MICVO and ...

November 3, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology to Present Translational Data and Key Biology Findings ...

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor cell killing, bystander effect, and immunogenic cell death Findings demonstrate MICVO’s effects on tumor microenvironment remodeling and immune activation Translational data to be presented in two posters at ESMO 2025 and six posters at AACR-NCI-EORTC ...

October 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch